Aligos Takes Another Hit with Halt of Hep B Therapy

Aligos Therapeutics, headquartered in South San Francisco, halted development of ALG-020572, which was being developed in patients with chronic hepatitis B (CHB). The first CHB cohort of Study ALG-020572-401 was stopped after one of the patients had a serious adverse event (SAE) causing a brief hospitalization.